Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 14/20 | 0.58 |
| ▸ | F10 | P00742 | 12/20 | 0.58 |
| ▸ | PLG | P00747 | 12/20 | 0.58 |
| ▸ | PLAU | P00749 | 12/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.58 |
| ▸ | PLAT | P00750 | 9/20 | 0.58 |
| ▸ | HPN | P05981 | 3/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.58 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.58 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29614824 | 1.00 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL29692564 | 1.00 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL1256806 | 1.00 | F2 (0.58) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL4259347 | 0.99 | F2 (0.56) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL419839 | 0.99 | F2 (0.59) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL29429330 | 0.99 | F2 (0.59) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL2874094 | 0.82 | F2 (0.59) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL29493199 | 0.78 | F2 (0.70) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL2864097 | 0.76 | PLAU (0.52) | F2F10PLGPLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL6785673 | 0.75 | F2 (0.62) | F2F10PLGPLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4723881-A1 | METHOD FOR GENERATING A HUMANIZED ANIMAL MODEL OF A MENTAL DISORDER FROM THE HUMAN OLFACTORY NEUROEPITHELIUM | Universidad de Cádiz (ES) | 2026-04-15 | — | — | EP | disclosed |
| US-20250154199-A1 | PEPTIDES FOR TREATING PAIN OR REDUCING PAIN SENSITIVITY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2025-05-15 | — | — | US | disclosed |
| WO-2024256342-A1 | METHOD FOR GENERATING A HUMANIZED ANIMAL MODEL OF A MENTAL DISORDER FROM THE HUMAN OLFACTORY NEUROEPITHELIUM | UNIVERSIDAD DE CÁDIZ (ES) | 2024-12-19 | — | — | WO | disclosed |
| EP-4477079-A1 | METHOD FOR GENERATING A HUMANIZED ANIMAL MODEL OF A MENTAL DISORDER FROM THE HUMAN OLFACTORY NEUROEPITHELIUM | Universidad de Cádiz (ES) | 2024-12-18 | — | — | EP | disclosed |
| EP-3723781-B1 | PEPTIDES AND OTHER AGENTS FOR TREATING PAIN AND INCREASING PAIN SENSITIVITY | UNIV NEW YORK STATE RES FOUND (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12077610-B2 | Peptides and other agents for treating pain and increasing pain sensitivity | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-09-03 | — | — | US | disclosed |
| EP-3990620-B1 | IN VITRO CELL CULTURE SYSTEM UNDER AEROBIC CONDITIONS SUITABLE FOR PHYSIOLOGICAL, PATHOLOGICAL, PHARMACOLOGICAL AND TOXICOLOGICAL INVESTIGATIONS | ARMATO UBALDO (IT) | 2023-12-13 | — | — | EP | disclosed |
| US-20230046305-A1 | PEPTIDES AND OTHER AGENTS FOR TREATING PAIN AND INCREASING PAIN SENSITIVITY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2023-02-16 | — | — | US | disclosed |
| US-11535649-B2 | Peptides and other agents for treating pain and increasing pain sensitivity | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220275417-A1 | METHOD FOR MANUFACTURING MONOCLONAL ANTIBODY USING YEAST, AND SCREENING METHOD | BARCODEBODY INC. (JP) | 2022-09-01 | — | — | US | disclosed |
| US-6767889-B1 | POLYPEPTIDE WITH HISTIDINE, GLYCINE, LEUCINE, AND LYSINE GROUPS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-27 | — | — | US | disclosed |
| WO-2003106631-A2 | METHODS AND COMPOSITIONS RELATING TO LABELED RNA MOLECULES THAT REDUCE GENE EXPRESSION | AMBION, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003077872-A2 | CELL SURFACE TROPOMYOSIN AS A TARGET OF ANGIOGENESIS INHIBITION | ATTENUON, LLC (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003075828-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | ZETIQ TECHNOLOGIES LTD. (IL) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003057906-A1 | A NEW VECTOR FOR GENETICALLY MODIFYING NON-HUMAN ANIMALS | BIOAGRI CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20020194638-A1 | Vector for genetically modifying non-human animals | WANG KANGSHENG (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002093130-A2 | METHODS OF ANALYZING CHROMOSOMAL TRANSLOCATIONS USING FLUORESCENCE IN SITU HYBRIDIZATION (FISH) | CANCER GENETICS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| EP-1137659-A1 | INHIBITION OF ANGIOGENESIS BY HIGH MOLECULAR WEIGHT KININOGEN AND PEPTIDE ANALOGS THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6255467-B1 | NUCLEOTIDE SEQUENCES FOR THE DETECTION OF MICOORGANISM IN SAMPLE | PATHOBIOTEK DIAGNOSTICS INC. | 2001-07-03 | — | — | US | disclosed |
| WO-2000027866-A1 | INHIBITION OF ANGIOGENESIS BY HIGH MOLECULAR WEIGHT KININOGEN AND PEPTIDE ANALOGS THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535649-B2 | Peptides and other agents for treating pain and increasing pain sensitivity | CALCA, CALCB, CALCRL | KLKB1 480/4885F2 2023/4885F10 1124/4885 |
| US-20230046305-A1 | PEPTIDES AND OTHER AGENTS FOR TREATING PAIN AND INCREASING PAIN SENSITIVITY | CALCA, CALCB, CALCRL | KLKB1 480/4885F2 2023/4885F10 1124/4885 |
| US-12077610-B2 | Peptides and other agents for treating pain and increasing pain sensitivity | CALCA, CALCB, CALCRL | KLKB1 480/4885F2 2023/4885F10 1124/4885 |
| US-20250154199-A1 | PEPTIDES FOR TREATING PAIN OR REDUCING PAIN SENSITIVITY | CALCA, CALCB, CALCRL | KLKB1 581/4885F2 2421/4885F10 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.